

Preliminary Programme



NOVEMBER 30 - DECEMBER 1, 2018

IOF REGIONAL SYDNEY'18

7TH ASIA-PACIFIC OSTEOPOROSIS CONFERENCE

ICC SYDNEY

www.iof-regional.org

Organizer
International Osteoporosis Foundation

Secretariat
www.humacom.com

Submit your
abstract now!

PRE-CONFERENCE COURSE

ACU North Sydney Campus

Nov 28 – 29, 2018

Osteoporosis: Essentials of Densitometry,
Diagnosis and Management Course

 facebook.com/iofbonehealth

 instagram.com/worldosteoporosisday

 twitter.com/iofbonehealth

 youtube.com/iofbonehealth



Our vision is a world without
fragility fractures in which
healthy mobility is a reality for all.
 www.iofbonehealth.org



Information

1. The Pre-Conference Courses will take place at the ACU (Australian Catholic University)
2. The Pre-Conference Courses can be booked separately or as part of the entire congress registration
3. The Opening Ceremony will take place at the ICC Sydney (International Convention Centre Sydney)
4. The Opening Ceremony is open to all duly registered delegates
5. The Exhibition Area is open on Friday from 08.30 to 18.00 and on Saturday from 08.00 to 17.00



Pre-Conference Courses

OSTEOPOROSIS: ESSENTIALS OF DENSITOMETRY, DIAGNOSIS AND MANAGEMENT COURSE

Wed, November 28 13.30 - 17.10

- 13.30 • *Welcome and Opening Remarks* – N. Pocock and A. Mithal
- 13.40 • *Overview of Osteoporosis* – N. Pocock
- 14.30 • *Bone Measurement Device Operating Principles* – S. Baldwin
- 15.20 *Coffee Break*
- 15.40 • *X-Ray Science, Radiation Safety and Quality Assurance* – N. Pocock
- 16.20 • *Clinical Evaluation of Bone Health* – D. Chan

Thu, November 29 08.00 - 17.00

- 08.00 • *Use of Bone Densitometry for the Diagnosis of Osteoporosis* – J. Center
- 08.50 • *Fracture Risk Assessment* – S. Baldwin
- 9.40 • *Monitoring Treatment of Osteoporosis* – J. Wark
- 10.30 *Coffee Break*
- 10.50 • *Clinical Management Part 1: Non-Pharmacologic, Estrogen & SERM Treatment*
- 11.40 • *Clinical Management Part 2: Pharmacological Treatment Continued* – J. Center



- 12.30 Lunch Break
- 13.30 • *Clinical Management Part 3: Further Pharmacologic Treatment Considerations* – M. Chandran
- 14.20 • *Principles of DXA Scan Interpretation* – N. Pocock
- 15.10 Coffee Break
- 15.30 • *Principles of Reporting DXA Scans* – N. Pocock
- 16.20 • *Cases for Discussion* – N. Pocock

Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

17.30 **OPENING CEREMONY**

- *Welcome* – C. Cooper, J. A. Kanis & M. Chandran
- *Best clinical papers of 2018* – R. Rizzoli
- *Inclusion of diversity in science* – S. Lee Brennan
- *Local CNS lecture: Hearing the Consumer voice* – G. Lyubomirsky
- *Osteoporosis, global challenge, local impacts* – L. March
- *Conclusion*

19.30 **WELCOME COCKTAIL**

20.30

Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

08.30 **EXHIBITION AREA OPEN**

18.00

08.30 **PLENARY SESSION I**

Improving the identification of high risk patients
Chair: J. A. Kanis & E. Seeman

- *Can FRAX be improved* – J. A. Kanis
- *CtF/FLS: what have we achieved* – C. Cooper
- *New imaging modalities* – S. Ferrari


Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

 10.00 **POSTER VIEWING AND EXHIBITION**

 10.00 **INDUSTRY-SPONSORED SATELLITE SYMPOSIUM** (Detailed programme on page 8)

 11.00 **PLENARY SESSION II**

Similarities and differences in fracture risk and treatments response: Asia vs West (IOF-OA session)

Chair: C. Cooper (IOF) & G. Liubomirsky (OA)

- *BMD and other parameters of bone in Asia vs West* Speaker – K. Sanders
- *FRAX: intervention threshold in Asia vs West* – E. Lau
- *Response to osteoporosis treatment: is it the same in Asian and Caucasian (benefit/risk including AFF)* – P. Ebeling

 12.30 **INDUSTRY-SPONSORED LUNCH SYMPOSIUM** (Detailed programme on page 8)

 13.30 **BREAK**

 14.00 **MEET-THE-EXPERT SESSIONS**

- *Recent Fracture: when and how to treat osteoporosis* – J.-K. Lee
- *Chronic renal failure: how to assess and manage bone fragility?* – P. Ebeling
- *Vitamin D: which & how much?* – A. Mithal
- *Protein intake and supplement in fracture patient* – R. Rizzoli

 14.45 **PLENARY SESSION III**

Quality of life in musculoskeletal diseases - ESCEO symposium

Chair: R. Rizzoli & E. Biver

- *Introduction* – O. Bruyère
- *Assessment of quality of life in osteoporosis* – J.-M. Kaufman
- *Assessment of quality of life in osteoarthritis* – N. Arden
- *Assessment of quality of life in sarcopenia* – F. Buckinx
- *Discussion* – J.-Y. Reginster
- *Conclusion* – J.-Y. Reginster



Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

16.15 IOF-APOA JOINT SESSION

Osteoporosis - Orthopedic Surgery in Asia Pacific, The Missing Link?

- Introduction – S. Ferrari
- Osteoporosis in Asia Pacific – P. Ebeling
- Orthopedic Surgery in Asia Pacific – D. Choon
- IOF-APOA Collaboration - "The Link" – J. K. Lee
- Launch of the IOF-APOA collaboration and Promising Future – C. Cooper

17.00 CNS ROUNDTABLE

Mapping calcium intake

Chair: B. Dawson-Hughes & A. Mithal

- Dietary calcium intake worldwide (Ca map) – B. Dawson-Hughes
- Consequences of low calcium intake in the Asia Pacific region – R. Rizzoli
- Calcium supplements and fracture prevention – A. Mithal
- Calcium intake and its implication in China – Wei-bo Xia
- Roundtable: Potential strategies to improve calcium intake - What is feasible within the low intake countries

18.30

Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1

08.00 EXHIBITION AREA OPEN

17.00

08.15 MEET-THE-EXPERT SESSIONS

- Falls prevention: is it possible – W. L. Hsu
- Bone loss in early menopause: to treat or not? – A. Vincent
- Genetic markers of bone fragility: what have we learned – E. Duncan
- Can we trust bone turnover markers to improve fracture assessment – H. Morris


Conference (ICC Sydney)

Thu, November 29

Fri, November 30

Sat, December 1
09.00 PLENARY SESSION V

Assessment and management of bone fragility beyond idiopathic osteoporosis (IOF-ANZBMS session)

Chair: S. Ferrari (IOF) & P. Croucher (ANZBMS)

- *Fracture prevention in cancer patients* – E. Biver
- *Fracture prevention in diabetes patients* – M. Chandran
- *When to suspect a genetic disorder?* – J. Eisman

10.30 POSTER VIEWING AND EXHIBITION
11.00 PLENARY SESSION VI

New insights in the management of knee osteoarthritis - ESCEO Symposium

Chair: C. Cooper & F. Cicuttini

- *Welcome* – C. Cooper
- *The 2014-2016 ESCEO algorithm for the management of knee osteoarthritis* – O. Bruyère
- *New insights on the safety of anti-osteoarthritis medications* – E. Dennison
- *New clinical evidence supporting the use of SYSADOAs as a first-line background treatment in knee osteoarthritis* – J.-Y. Reginster, G. Honvo, A. Geerinck, O. Bruyère
- *Update of the 2014-2016 ESCEO algorithm for the management of knee osteoarthritis* – C. Cooper
- *Discussion* – C. Cooper
- *Conclusion* – J.-Y. Reginster

12.30 INDUSTRY-SPONSORED SATELLITE SYMPOSIUM (Detailed programme on page 8)
13.30 BREAK
14.00 IOF-OA-ANZBMS JOINT SESSION

Chair: G. Lyubomirsky & B. Dawson-Hughes

- *Exercise and osteoporosis* – B. Beck
- *Monetary cost of osteoporosis* – J. A. Kanis
- *Morbidity and mortality of osteoporosis* – J. Center

14.45 YOUNG INVESTIGATOR AWARDS SESSION



Conference (ICC Sydney)		
Thu, November 29	Fri, November 30	Sat, December 1
14.45	MEET-THE-EXPERT SESSIONS <ul style="list-style-type: none"> • <i>Osteosarcopenia</i> – G. Duque • <i>Glucocorticoid osteoporosis</i> – E. Dennison • <i>Assessment of physical strength and performance</i> – F. Buckinx 	
15.45	PLENARY SESSION VII <i>Osteoporosis treatment: update</i> Chair: J.-Y. Reginster & A. Mithal <ul style="list-style-type: none"> • <i>Benefit/Risk of long term treatment</i> – S. Ferrari • <i>Fracture risk off therapy</i> – E. Dennison • <i>Closing the gap in the treatment of patients at imminent risk of fracture: role of the new anabolic agents</i> – J.-Y. Reginster 	
17.00		



Industry-Sponsored Symposia

Thu, November 29	Fri, November 30	Sat, December 1
	<p>MEDTRONIC SATELLITE SYMPOSIUM</p> <p><i>UNDERSTANDING MORTALITY RISK FOR PATIENTS WITH VCF</i> Chair: K. L. Ong</p> <ul style="list-style-type: none"> • <i>Understanding mortality risk for patients with VCF – K. L. Ong</i> 	
	<p>AMGEN SATELLITE SYMPOSIUM</p> <p><i>ACHIEVING THE GOALS OF OSTEOPOROSIS THERAPY</i></p> <ul style="list-style-type: none"> • <i>Arrivals and welcome – P. Ebeling</i> • <i>Presentation and Q & A – S. Ferrari</i> • <i>Long term treatment – case study – K. M. Kim</i> • <i>Panel discussion – All</i> 	

Thu, November 29	Fri, November 30	Sat, December 1
		<p>ELI LILLY SATELLITE SYMPOSIUM</p> <p><i>THE IMPORTANCE OF BONE FORMING AGENTS IN THE TREATMENT OF SEVERE OSTEOPOROSIS</i> Chairperson: D. Thiebaud</p> <ul style="list-style-type: none"> • <i>Welcome & Introduction – D. Thiebaud</i> • <i>Differing Effects of Antiresorptive and Anabolic Therapies on Bone Structure – E. Seeman</i> • <i>Differential Effects of Teriparatide VS Antiresorptives on Osteoporotic Fractures – S. Ferrari</i> • <i>Audience Questions and Answers – All Panel</i> • <i>Closing Remarks – D. Thiebaud</i>